BACKGROUND: Non-ulcer dyspepsia (NUD) is a heterogeneous disorder, which is characterized by upper gastrointestinal symptoms and sensorimotor disturbances, including abnormal gastric emptying (GE) and increased intestinal chemosensitivity, and associated with greater plasma glucagon-like peptide-1 (GLP-1) levels during duodenal lipid infusion. However, the relationship(s) between these disturbances and daily symptoms in NUD is variable. We hypothesize that abnormal GE and symptoms during a GE study and during duodenal lipid infusion are associated with the severity of daily symptoms and that GLP-1 mediates symptoms during duodenal lipid infusion in NUD. METHODS: Gastric emptying of solids, symptoms during the GE study and duodenal lipid infusion, and daily gastrointestinal symptoms (2 week diary) were measured in 24 healthy controls and 40 NUD patients. During duodenal lipid infusion, participants received the GLP-1 antagonist exendin 9-39 or placebo. KEY RESULTS: In controls and patients, GE of solids was normal in 75% and 75%, delayed in 8% and 12.5%, or rapid in 17% and 12.5%, respectively. No controls but 26 patients (65%) had severe symptoms during the GE study. During lipid infusion, gastrointestinal symptoms were greater (P = .001) in patients and not affected by exendin. Symptoms during GE study and lipid infusion accounted for respectively 62% and 37% of variance in daily symptom severity. CONCLUSIONS: In NUD, symptoms during a GE study and to a lesser extent during lipid infusion explain the variance in daily symptoms. Intestinal chemosensitivity is not reduced by GLP-1 antagonist. Assessment of symptoms during a GE study may provide a useful biomarker for NUD in research and clinical practice.
BACKGROUND:Non-ulcer dyspepsia (NUD) is a heterogeneous disorder, which is characterized by upper gastrointestinal symptoms and sensorimotor disturbances, including abnormal gastric emptying (GE) and increased intestinal chemosensitivity, and associated with greater plasma glucagon-like peptide-1 (GLP-1) levels during duodenal lipid infusion. However, the relationship(s) between these disturbances and daily symptoms in NUD is variable. We hypothesize that abnormal GE and symptoms during a GE study and during duodenal lipid infusion are associated with the severity of daily symptoms and that GLP-1 mediates symptoms during duodenal lipid infusion in NUD. METHODS: Gastric emptying of solids, symptoms during the GE study and duodenal lipid infusion, and daily gastrointestinal symptoms (2 week diary) were measured in 24 healthy controls and 40 NUD patients. During duodenal lipid infusion, participants received the GLP-1 antagonist exendin 9-39 or placebo. KEY RESULTS: In controls and patients, GE of solids was normal in 75% and 75%, delayed in 8% and 12.5%, or rapid in 17% and 12.5%, respectively. No controls but 26 patients (65%) had severe symptoms during the GE study. During lipid infusion, gastrointestinal symptoms were greater (P = .001) in patients and not affected by exendin. Symptoms during GE study and lipid infusion accounted for respectively 62% and 37% of variance in daily symptom severity. CONCLUSIONS: In NUD, symptoms during a GE study and to a lesser extent during lipid infusion explain the variance in daily symptoms. Intestinal chemosensitivity is not reduced by GLP-1 antagonist. Assessment of symptoms during a GE study may provide a useful biomarker for NUD in research and clinical practice.
Authors: Kevin J Donohoe; Alan H Maurer; Harvey A Ziessman; Jean-Luc C Urbain; Henry D Royal; J Martin-Comin Journal: J Nucl Med Technol Date: 2009-08-19
Authors: M Camilleri; J Iturrino; A E Bharucha; D Burton; A Shin; I-D Jeong; A R Zinsmeister Journal: Neurogastroenterol Motil Date: 2012-07-02 Impact factor: 3.598
Authors: Daniel Pohl; Lukas Van Oudenhove; Hans Törnblom; Boris Le Nevé; Jan Tack; Magnus Simrén Journal: Clin Gastroenterol Hepatol Date: 2018-04-24 Impact factor: 11.382
Authors: Priya Vijayvargiya; Sina Jameie-Oskooei; Michael Camilleri; Victor Chedid; Patricia J Erwin; Mohammad Hassan Murad Journal: Gut Date: 2018-06-02 Impact factor: 23.059
Authors: Chinmay S Marathe; Christopher K Rayner; Michelle Bound; Helen Checklin; Scott Standfield; Judith Wishart; Kylie Lange; Karen L Jones; Michael Horowitz Journal: Diabetes Date: 2014-04-02 Impact factor: 9.461
Authors: Meera Shah; Jennie H Law; Francesco Micheletto; Matheni Sathananthan; Chiara Dalla Man; Claudio Cobelli; Robert A Rizza; Michael Camilleri; Alan R Zinsmeister; Adrian Vella Journal: Diabetes Date: 2013-10-02 Impact factor: 9.461
Authors: Anshuman Desai; Phillip A Low; Michael Camilleri; Wolfgang Singer; Duane Burton; Subhankar Chakraborty; Adil E Bharucha Journal: Neurogastroenterol Motil Date: 2019-10-22 Impact factor: 3.598
Authors: Christopher J Black; Peter A Paine; Anurag Agrawal; Imran Aziz; Maria P Eugenicos; Lesley A Houghton; Pali Hungin; Ross Overshott; Dipesh H Vasant; Sheryl Rudd; Richard C Winning; Maura Corsetti; Alexander C Ford Journal: Gut Date: 2022-07-07 Impact factor: 31.793
Authors: Henry P Parkman; Mark L Van Natta; Alan H Maurer; Kenneth L Koch; Madhusudan Grover; Zubair Malik; Irene Sarosiek; Thomas L Abell; Robert Bulat; Braden Kuo; Robert J Shulman; Gianrico Farrugia; Laura Miriel; James Tonascia; Frank Hamilton; Pankaj J Pasricha; Richard W McCallum Journal: Am J Physiol Gastrointest Liver Physiol Date: 2022-05-03 Impact factor: 4.871
Authors: Susrutha Puthanmadhom Narayanan; David R Linden; Stephanie A Peters; Anshuman Desai; Saatchi Kuwelker; Daniel O'Brien; Thomas J Smyrk; Rondell P Graham; Madhusudan Grover; Adil E Bharucha Journal: Neurogastroenterol Motil Date: 2020-08-09 Impact factor: 3.598
Authors: Susrutha Puthanmadhom Narayanan; Daniel R O'Brien; Mayank Sharma; Thomas C Smyrk; Rondell P Graham; Madhusudan Grover; Adil E Bharucha Journal: Clin Gastroenterol Hepatol Date: 2021-10-02 Impact factor: 13.576